

7 July 2025

## EVE SUBMITS FIRST COMMERCIAL PURCHASE ORDER FOR DYSPRO™

- EVE has issued the first commercial purchase order for Dyspro™, ahead of the product launch timeline.
- Dyspro™ is a pharmaceutical-grade formulation containing a validated blend of cannabinoid-derived active ingredients, developed in-house to support women's health.
- The order initiates the manufacturing process at a third-party GMP-certified Australian facility.
- Product is expected to be ready for distribution within five weeks.
- Dysmenorrhoea (painful menstruation) represents a growing global treatment market, forecast to reach USD 20 billion by 2035<sup>3</sup>.
- Dyspro™ will be manufactured and distributed in accordance with all applicable requirements under the Australian regulatory framework.
- Distribution will be supported by a prescriber engagement and fulfilment partnership with TeleDocs Clinic, with further opportunities under review.
- Regulatory pathway complete with EVE's prescribing network already authorised; supporting swift commercial uptake.

**EVE Health Group Limited (ASX: EVE, EVE or the Company)** is pleased to advise that it has submitted the first commercial purchase order (PO) for Dyspro™, the Company's proprietary gummy-format cannabinoid-based pharmaceutical product developed to support women experiencing dysmenorrhoea (painful menstruation) and related health concerns.

The submission of this first PO marks a significant operational milestone following EVE's acquisition of Nextract, and its expansion into prescription pharmaceutical products. Dyspro™ represents the Company's first internally developed product to progress from formulation to scaled manufacturing.

### Path to Commercial Launch and Prescriber Readiness

A wide network of authorised prescribers across Australia already have approval to prescribe Dyspro, and no further regulatory steps are required to enable commercial supply. EVE's network of prescribing doctors is already authorised, and nurse practitioners can obtain patient-specific approvals within one business day, valid for 24 months. These streamlined prescribing pathways position the product for rapid uptake following launch.

EVE is currently assessing distribution options to support the national fulfilment of Dyspro™. While several partners with proven pharmaceutical logistics capabilities are under active consideration, a final distribution partner has not yet been appointed. The Company is focused on selecting a solution that ensures timely access, compliance with all regulatory handling requirements, and scalable infrastructure to support growth in demand.

**Background on Dysmenorrhoea and Endometriosis**

Dysmenorrhoea, or painful menstruation, is a prevalent condition among Australian women of reproductive age. A recent study found that 77% of women aged 18–44 reported experiencing bothersome menstrual symptoms, with the highest prevalence observed in the 18–24 age group. These symptoms significantly impact daily activities, with 44% of respondents reporting missed days of work or study due to their menstrual symptoms.<sup>1</sup>

The economic implications are substantial, with the annual burden of menstrual symptoms in Australia estimated at approximately AUD \$14.2 billion, primarily due to lost productivity.

In more severe cases, Dysmenorrhoea (painful menstruation) may be associated with endometriosis, a chronic inflammatory condition estimated to affect up to 10% of reproductive-age women. A national survey found that the average annual cost of illness per woman with chronic pelvic pain (with or without endometriosis) ranged from US\$16,970 to US\$20,898, with 75–84% of costs attributed to lost productivity.<sup>2</sup>

**Market Opportunity**

Dysmenorrhoea (painful menstruation) and endometriosis are highly prevalent and under-addressed women’s health conditions, representing a substantial and growing global treatment market.




Figure 1: Global Dysmenorrhoea Treatment Market (2024–2035), IMARC Group

<sup>1</sup> Mardon A.K. et al. *Problematic Periods Costing Young Women—The Impact of Menstrual Symptoms on Work and Study*. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 2024. <https://obgyn.onlinelibrary.wiley.com/doi/10.1111/ajog.13926>

<sup>2</sup> Armour M. et al. *The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey*. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223316>

Figures in Armour et al. (2019) were originally reported in 2017 International dollars (Int \$), using purchasing power parity (PPP) to approximate US dollar values. These are expressed in USD here for clarity.

The global Dysmenorrhoea treatment market reached USD 10.9 billion in 2024 across the top seven pharmaceutical markets (US, EU4, UK, and Japan). The market is forecast to grow at a compound annual growth rate (CAGR) of 5.73% to reach USD 20.0 billion by 2035.<sup>3</sup>

Australia endometriosis treatment market, 2018-2030 (US\$M)




Figure 2: Australian Endometriosis Treatment Market (2019–2030), Grand View Research

In parallel, the Australian endometriosis treatment market—where endometriosis is often comorbid with Dysmenorrhoea—is expected to grow strongly. According to Grand View Research, this market is projected to reach USD 76.4 million by 2030, growing at a CAGR of 13% from 2025.<sup>4</sup>

### TeleDocs Clinic partnership

As previously announced, EVE signed an agreement with TeleDocs, a nationally licensed Australian telehealth provider. TeleDocs will offer digital consults for the management of women’s health with appropriately trained medical practitioners.

The collaboration with TeleDocs ensures that the product launch is underpinned by a compliant and scalable prescriber network, with a focus on women’s health and responsible access to cannabinoid-based medicine.

**Commenting on the milestone, Executive Director and Chief Scientific Officer Dr Stuart Gunzburg said:** “Submitting the first commercial purchase order for Dyspro™ signals our readiness to deliver on the next phase of EVE’s growth strategy. We’re proud to see our internal formulation efforts translating into a tangible product that will soon be available to support women’s health through regulated prescription channels.”

Further updates will be provided as manufacturing progresses and commercial rollout preparations are finalised.

Authorised for release by the Board of Directors.

<sup>3</sup> IMARC Group, *Dysmenorrhea Market Outlook 2025–2035*, [www.imarcgroup.com/dysmenorrhea-market](http://www.imarcgroup.com/dysmenorrhea-market)

<sup>4</sup> Grand View Research, *Australia Endometriosis Treatment Market Outlook*, [www.grandviewresearch.com/horizon/outlook/endometriosis-treatment-market/australia](http://www.grandviewresearch.com/horizon/outlook/endometriosis-treatment-market/australia)

For personal use only

— ENDS —

**Company enquiries**

+61 8 6465 5500

info@evehealthgroup.com.au

**About EVE Health Group**

EVE Health Group (ASX: EVE) is an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nextract EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy and clinical channels.

For further information, please visit [www.evehealthgroup.com.au](http://www.evehealthgroup.com.au) and follow us on LinkedIn.

For personal use only